Figure1 The identification of the 8F1 cross-reactive protein with protein microarray chip and Western blot confirmation. A. Protein microarray hybridization with 8F1. The OriGene overexpression protein microarray chip was immunostained with the most commonly used 8F1 monoclonal anti-ERCC1 antibody. The positive reactive proteins are highlighted with red arrows. These data show that 8F1 recognizes not only its specific target (two ERCC1 transcript variants), but also another unrelated nuclear membrane protein PCYT1A. A number of internal controls were also labeled on the panel. B. Western Blot analysis. Seven OriGene VERIFY overexpression lysate antigen standards (Lane 1 to 7) were fractionated on SDS-PAGE, and then immunoblotted with 8F1 (Upper panel)。 The recombinant protein expression levels within the lysates were analyzed with anti-DDK antibody (Lower panel)。 Lanes 1 to 7 are loaded with samples for ERCC1 (NM_202001), ERCC1 (NM_001983), ERCC2 (NM_000400), ERCC3 (NM_000122), ERCC4 (NM_005236), ERCC5 (NM_000123) and PCYT1A (NM_005017)。
Figure2 To develop the most highly specific anti-ERCC1 monoclonal antibody with a protein microarray chip. A. Specificity evaluation with a protein microarray chip. The overexpression protein microarray chip was immunostained with the 4F9 clone. This data shows that 4F9 is highly specific to ERCC1 (indicated with red arrows)。 No cross-reactivity was observed with any other test protein. B. Western Blot confirmation analysis. Seven OriGene VERIFYTM overexpression lysate antigen standards (Lane 1 to 7) were fractionated on SDS-PAGE, and then immunoblotted with 4F9. The recombinant protein expression levels for the each of the different protein overexpression lysates were confirmed with the anti-DDK antibody (Figure 2B)。 Lanes 1 to 7 are loaded with samples for ERCC1 (NM_202001), ERCC1 (NM_001983), ERCC2 (NM_000400), ERCC3 (NM_000122), ERCC4 (NM_005236), ERCC5 (NM_000123) and PCYT1A (NM_005017)。
1.Donghui,Dror Baruch, Youmin Shu:Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology.BMC Biotechnology201212:88doi.org/10.1186/1472-6750-12-88.
2. Coleman MH, Bueno R: Role of adjuvant chemotherapy in NSCLC (stages I to III)。 Surg Oncol Clin N Am. 2011, 20 (4): 757-767. 10.1016/j.soc.2011.07.011.
3. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB: Mechanisms of Cisplatin nephrotoxicity. Toxins. 2010, 2 (11): 2490-2518. 10.3390/toxins2112490.